Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418740 · ClinicalTrials.gov registry record
Neurology Measures in FA Children
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 108
- Enrollment target
NCT03418740: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT03418740 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03418740 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to identify ways to follow progression of Friedreich's Ataxia (FA) and be able to measure changes over time in children with FA. Participants will have biannual visits to observe how the disease progresses over time and determine the rate of progression. Funding Source- Food and Drug Administration Office of Orphan Products Development (FDA OOPD).
Primary Outcome
The Friedreich Ataxia Rating Scale (FARS) measures neurological function in FA. It is a composite measure reflecting neural substrates with five-subscales (sections A to E), measuring bulbar function, upper limb coordination, lower limb coordination, peripheral nerves, and upright stability. The modified FARS (mFARS) shortens the bulbar subscale to 2 items and excludes the peripheral nerve subscale. Total scoring is a summation of subscales, with a maximum score of 93 points for mFARS and 125 f
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2023-02-02 |
What the finished NCT03418740 record still lists
NCT03418740 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03418740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03418740 about?
NCT03418740 is a clinical study titled "Neurology Measures in FA Children". The purpose of this study is to identify ways to follow progression of Friedreich's Ataxia (FA) and be able to measure changes over time in children with FA. Participants will have biannual visits to observe how the disease progresses over time and determine the rate of progression. Funding Source-...
What is the current status of trial NCT03418740?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2017-11-20. Estimated completion is 2023-02-02.
Who is sponsoring clinical trial NCT03418740?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI